Eisai and Biogen received US regulatory approval for a new self-injected form of their Alzheimer’s drug Leqembi, in a move that could make a complicated treatment regimen more convenient for patients taking the drug long term https://t.co/3TkmmUjTiT ...

Funding & Investment - Illimis Therapeutics secured 580 亿韩元 (approximately $42 million) in funding [1] - The funding aims to support research into Alzheimer's disease treatments [1] - The funding will also facilitate expansion into immune diseases [1]